A small, nonconjugative plasmid, designated pBP1, was originally found in different fecal Escherichia coli serotypes isolated from a healthy proband. Of a total number of 130 hospital strains of E. coli subsequently studied, 8.5% yielded plasmids of the pBP1 type. This R plasmid specifies resistance to streptomycin (Sm) and sulfonamides (Su) and has a mass of 4.0 megadaltons. Inactivation of streptomycin is due to the aminoglycoside phosphotransferase APH-(3"). A physical map was constructed by analysis with restriction endonucleases. Another small plasmid, pBP1-1, was isolated from one of the hospital strains and characterized as an enlarged pBP1 replicon containing an additional deoxyribonucleic acid sequence identified as a transposable element for ampicillin resistance (TnA). Plasmid pBP1-1 was cleaved by restriction enzymes for identification of the transposon sequence which codes for a TEM 1 f8-lactamase. The sequence organizations in the Sm Su plasmids RSF1010 and pBP1 were shown to be identical for regions specifying streptomycin and sulfonamide resistance, but different for the region containing the origin of replication and genes for replicative functions. Thus, RSF1010, which has been considered as the prototype of Sm Su plasmids, and pBP1, which is at least as frequent in clinical isolates as RSF1010, do not have a single common ancestor.
Although the use of streptomycin is restricted to the therapy of tuberculosis in most countries, the incidence of streptomycin resistance (Smr) in clinical isolates has been shown to be very high, with a level of about 25% in central Europe (24). Smr is usually mediated by plasmid-specified adenylyl-or phosphotransferases. It has been suggested that all nonconjugative plasmids with Smr inactivate this drug by phosphorylation, whereas the conjugative plasmids inactivate mostly by adenylylation (20) .
Smr linked with resistance to sulfonamides (Sur) represents a common group of plasmidborne drug resistance patterns. The relationship between Sm Su plasmids from various Salmonella spp. and Escherichia coli strains derived from compatibility testing shows incompatibility in 19 out of 26 strains with Smr Sur (29) . The described Sm Su plasmids were presumed to be closely related to the original Sm Su replicon NTP2 of Anderson and Lewis (2) .
Other R plasmids mediating linked streptomycin and sulfonamide resistance have been characterized in more detail (3, 13) . Out of 12 of the plasmids belonging to incompatibility group Inc Q, 10 have a molecular mass of 5.5 to 6.3 megadaltons and a single cleavage site for restriction endonuclease EcoRI. Deoxyribonucleic acid (DNA)-DNA hybridization and heteroduplex analysis revealed a close overall homology between these replicons and RSF1010, a 5.5-megadalton plasmid also conferring streptomycin and sulfonamide resistance (16) .
Exact epidemiological data on Sm Su plasmids from clinical specimens were not available until recently. This paper is concerned with the physical characterization and dissemination of plasmid pBP1, specifying Smr and Sur but differing from the group described above in having a size of 4.0 megadaltons. Its sequence homology with RSF1010 was studied, and a related plasmid, pBPl-1, with an integration of a transposon coding for ampicillin resistance (Apr) was analyzed.
MATERIALS AND METHODS
Bacterial strains and plasmids. Laboratory strains of E. coli and standard plasmids used are listed in Table 1 (10) , spread with 100 ,ug of cytochrome c per ml over a hypophase consisting of freshly distilled water, and mounted on 1.5% Parlodion-coated grids. Contour lengths of molecules were measured on electron micrographs by using a map measurer. 4X174 single-and double-stranded DNAs were used as internal standards (28) .
Transformation of plasmid DNA. The transformation was carried out essentially by the method of Humphreys et al. (17) . The selective agar contained 10,g of streptomycin or 500 ,ug of sulfonamide per ml.
Transposition of an Ap marker onto the plasmids pUB307 and R751. Logarithmically growing cells of the donor strains UB281 (pUB307) and UB281 (R751) described in Table 1 [Rifri) . RESULTS Origin and characterization of plasmid pBP1. Different E. coli serotypes (017, 057, and 0106) resistant to streptomycin and sulfonamide were isolated from a single healthy proband in Frankfurt and examined for the presence of extrachromosomal DNA. Ethanol-precipitated DNA from cleared lysates was subjected to agarose gel electrophoresis. In addition to several high-and low-molecular-mass plasmids, all of the resistant strains contained a common, 4.0-megadalton R plasmid. Transformation of E. coli C600 with purified plasmid DNA by using streptomycin and sulfonamide as selective drugs demonstrated that the replicons recovered in the transformants mediate linked resistance to streptomycin and sulfonamides. The Sm Su plasmid derived from E. coli of serotype 057 (strain 14518) was designated pBP1. The minimal inhibitory concentration for sulfonamide was 8,000 ,ug/ml, and the minimal inhibitory concentration for streptomycin was 512 ,ig/ml.
Characterization of the streptomycin-inactivating enzyme encoded by pBP1 revealed an aminoglycoside phosphotransferase, APH-(3").
Physical analysis of pBP1 was obtained from plasmid DNA subjected to agarose gel electrophoresis after digestion with restriction endonucleases ( (Fig. 1) . All fragments were aligned to best fit the restriction map of pBP1 in Fig. 2 Incidence of plasmids in clinical isolates resembling pBP1. A total of 130 strains of E. coli isolated in Bonn from clinical specimens (predominantly from urinary tract infections) were screened for Smr Sur and sensitivity to spectinomycin (Sp') ( Table 3) according to the resistance pattern specified by pBPl. All strains with the phenotype Smr Sur sp' possessed an APH-(3") phosphotransferase with activity equivalent to that expressed by plasmid JR66, which was used as a standard for this activity (6) . None of the strains expressed detectable adenylyltransferase activity. The number and molecular masses of the plasmid DNAs obtained from these strains were determined by agarose short inverted repeat (IR). revealed heterogenous restriction patterns, whereas HindII generated two corresponding fragments, 1.35 and 0.5 megadaltons in size (Fig.  7) , in both plasmids, the latter of which was cleaved by PstI at the same site in both pBP1 and RSF1010.
A typical heteroduplex structure of pBP1 and RSF1010 is presented in Fig. 8 , revealing a homologous segment interrupted by cleavage with EcoRI used as an internal marker. According to this structure only half of the plasmid pBP1 is homologous to RSF1010 (51.4%). By comparison of the length calculation of the heteroduplex molecule with maps of both plasmids (27, 31) , the position of streptomycin and sulfonamide resistance genes could be localized on pBP1 in the region of homology (Fig. 9) Several other plasmids also conferring Sur and Smr, but larger than pBP1, have been described by different workers (3, 13, 27, 29, 31) . The prototype of this plasmid group is NTP2, initially described by Anderson and Lewis (2), which is identical to plasmid RSF1010. Plasmids of this group, present as multicopy pools, were found to be efficiently mobilized to their wide host range by many groups of R plasmids and to be largly homologous with each other. Thus, it can be suggested that a single plasmid evolved once and has spread efficiently with relatively few modifications. As Smr is mediated by the same inactivating enzyme [APH-(3")] in plasmids RSF1010 and pBP1, we looked for further relatedness between these plasmids. Our heteroduplex study revealed homology between pBP1 and RSF1010 for a length of 1.47 megadaltons from the designated EcoRI left end and 0.56 megadaltons from the other end (Fig. 9) . Thus, the region of homology includes the structural genes for Sur and Smr mapped by Rubens et al. (27) and thereby specifies their location in pBP1. However, the origin of replication, 30.7% (about ANTIMICROB. AGENTS CHEMOTHER.
on July 2, 2017 by guest http://aac.asm.org/ Downloaded from 1.7 megadaltons) from the left end of RSF1010 (11) , is located in the region of nonhomology. It has been shown that insertions of TnA nearby 40% from the left end have a profound effect on the copy number of RSF1010 within host cells (11) . This region was associated with the replicative functions of RSF1010, suggesting that the replication genes are not identical to those of pBP1. Finally, proof that pBP1 is not a modification of RSF1010 was obtained by compatibility testing (unpublished observations). Plasmid pBP1-1 (pBPl::TnA) was stably introduced into a strain carrying plasmid RSF1010, which belongs to incompatibility group Inc Q. We therefore conclude that dissemination of identical resistance genes occurs on different replicons, which have arisen independently. Plasmid pBPl seems to be a very stable molecule which is more common in E. coli than are other Sm Su resistance plasmids. It is surprising that in the strains under investigation we did not find any plasmids similar to RSF1010.
The replicon pBP1 serves as vehicle for other drug resistance markers such as Apr as demonstrated with the enlarged plasmid pBP1- We are now looking for the spread of group pBP1 plasmids in human and animal E. coli strains isolated in Bristol, Great Britain. The early results have shown that pBP1 occurs not only in the feces of humans, but also in feces of chicken and cattle.
